SPY AGENT GREEN KIT

Peak

indocyanine green

NDAINTRAVENOUS, INTERSTITIALPOWDER
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3

Clinical Trials (3)

NCT06672224N/AWithdrawn

Indocyanine Green Fluoroscopy and SPY Angiography for the Assessment of Lymphatic Structure in Breast Cancer Patients at Risk for Breast Cancer-Related Lymphedema

Started Aug 2025
NCT06084013N/ARecruiting

Use Of Indocyanine Green In Pancreas Surgery

Started May 2024
55 enrolled
Pancreatic Carcinoma
NCT06024213N/ACompleted

A French Observational Study of Indocyanine Green for Patients With Breast Cancer Having a Sentinel Lymph Node Biopsy.

Started Jun 2023
101 enrolled
Breast Cancer

Loss of Exclusivity

LOE Date
Jul 14, 2039
162 months away
Patent Expiry
Jul 14, 2039
Exclusivity Expiry
Jun 5, 2026

Patent Records (5)

Patent #ExpiryTypeUse Code
8185176
Jun 4, 2028
U-2462
8647605
Feb 11, 2029
U-2464
8406860
Apr 9, 2029
U-2463
10631746
Aug 4, 2035
Product
U-2815
11712320
Jul 14, 2039
Product
—
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers